Juniper Pharma (JNP) Misses Q1 EPS by 4c

Juniper Pharma (NASDAQ: JNP) reported Q1 EPS of ($0.13), $0.04 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $11.2 million versus the consensus estimate of $11.27 million.

• Board and Committee Composition Matters Juniper also announced today that Frank Condella will not seek re-election to the Company\'s Board of Directors at the upcoming annual shareholder meeting, as a result of which his term in office will expire upon completion of the meeting.

For earnings history and earnings-related data on Juniper Pharma (JNP) click here.

You May Also Be Interested In

• AngioDynamics (ANGO) Tops Q1 EPS by 7c, Beats on Revenue; Offers F27 Revenue Guidance
• BlackRock (BLK) PT Lowered to $1,230 at Wells Fargo
• Neogen Corp. (NEOG) Tops Q1 EPS by 3c; raises guidance